AXSM:NSD-Axsome Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.82

Change

+2.92 (+10.47)%

Market Cap

USD 0.99B

Volume

0.57M

Avg Analyst Target

USD 56.75 (+84.13%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Axsome Therapeutics Inc (AXSM) Stock Analysis:
Based on the Axsome Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Axsome Therapeutics Inc is USD 56.75 over the next 12 months. Axsome Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axsome Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Axsome Therapeutics Inc’s stock price was USD 30.82. Axsome Therapeutics Inc’s stock price has changed by +14.91% over the past week, -16.39% over the past month and -47.24% over the last year.

About

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and ...Read More

Company Website : https://www.axsome.com

Address : 22 Cortlandt Street, New York, NY, United States, 10007

Employees : 108

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.41

52 Week High : 74.10

Short Ratio : 6.02

52 Week Low : 19.38

Shorted Shares : 4,520,204

200 Day Moving Average : 33.50

Shorted Shares Previous Month : 4,560,466

50 Day Moving Average : 35.09

Shares Held By Insiders : 20.56%

Short Percentage : 14.75%

Shares Held by Institutions : 48.79%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

 USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

 USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

 USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

 USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

 USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

 USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

 USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

 USD16.75B N/A N/A

ETFs Containing AXSM

Symbol Name Weight Mer Price(Change) Market Cap
DWAQ Invesco DWA NASDAQ Moment.. 0.00 % 0.60 %

N/A

 USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.42% 83% B 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.42% 83% B 52% F
Trailing 12 Months  
Capital Gain -47.73% 67% D+ 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.73% 67% D+ 33% F
Trailing 5 Years  
Capital Gain 721.87% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 721.87% 95% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 264.42% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 264.42% 96% A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 573.87% 4% F 3% F
Risk Adjusted Return 46.08% 83% B 74% C
Market Capitalization 0.99B 86% B 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 68.28 2% F 1% F
Price / Cash Flow Ratio -9.11 80% B- 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -201.51% 12% F 6% F
Return on Invested Capital -109.95% 20% F 10% F
Return on Assets -56.91% 11% F 4% F
Debt to Equity Ratio 314.07% 6% F 7% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.02 42% F 26% F
Short Percent 14.75% 11% F 12% F
Beta 2.41 7% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector